Capital Markets Day 2023 - Ipsen next phase of growth, new mid-term outlook

 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.

“Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results.

Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and roadmap with our Generation Ipsen program, based on Environment, Patients, People, and Governance.

As a significantly more diversified business across our three therapeutic areas and a geographically well-balanced company, we now have many sustainable and attractive growth opportunities across our portfolio and pipeline to create long-term value for all of our stakeholders and investors.”

Strategic outlook 2027

• Several current and potential near-term launches, including Onivyde^® (irinotecan), Bylvay^® (odevixibat), elafibranor and Sohonos^® (palovarotene), complemented by many pipeline milestones over the mid term
• A strengthened and diversified business: a combination of seven anticipated and current medicines, each with expected peak sales of at least €500m
• A global footprint and strong portfolio opportunity in the U.S.
• External innovation: active business-development focus providing a platform to drive sustainable pipeline growth
• ESG roadmap: ambitious Generation Ipsen goals for positive change to achieve net-zero emissions by 2045 and foster Ipsen’s culture centered on patients and society

Financial outlook

• Total-sales average growth of at least 7% per year for the period 2023-27 and at constant exchange rates
• Core operating margin in 2027 of at least 32% of total sales

This outlook excludes the impact of any potential additional late-stage¹ external-innovation opportunities. The priority for capital allocation remains focused on external-innovation transactions across the three therapeutic areas while maintaining net debt, including contingent liabilities, below 2.0 times EBITDA.

Agenda
Today’s event will include the following participants:

• David Loew, Chief Executive Officer
• Aymeric Le Chatelier, Chief Financial Officer
• Christelle Huguet, Head of R&D
• Bartek Bednarz, Head of Global Product ​& Portfolio Strategy
• Stewart Campbell, President, North America
• Mari Scheiffele, President, International

Event details
Today’s event will start at 12.30pm GMT, 1.30pm CET in London, with attendance by invitation only. The event will be webcast live; all participants will have an opportunity to ask questions and can access webcast details here. A recording will be available on ipsen.com.

https://www.biospace.com/article/releases/capital-markets-day-2023-ipsen-outlines-next-phase-of-growth-and-transformation-and-provides-new-mid-term-outlook/